Nicholas Edwards
Chairman @Prescient
Signup · Get unlimited contacts
WORK HISTORY
Chairman @Prescient
Prescient partners with biopharmaceutical companies to help them shape asset and portfolio strategies across the life cycle to maximise clinical and commercial value. Services include competitive intelligence, commercial and medical strategy support. Baird Capital invested in the business from 2017 to 2021 - during which time the enterprise value was increased from £30m to £160m over the four year holding period, delivering an IRR of 59%. Since 2021 the major investor has been Bridgepoint and there have been two acquisitions - Strategic North and Uptake Strategies.
EDUCATION
University of Oxford
BM, BCh, Clinical Medicine
University of Oxford
BA, Physiological Science
SKILLS
ABOUT NICHOLAS EDWARDS
Medical doctor with experience of consulting and new business creation in healthcare, life sciences and bio-pharmaceuticals.Works with large pharmaceutical companies, regulatory bodies, start up and small businesses in the healthcare, pharmaceutical, biotechnology medical or diagnostic devices area. Interested in supporting the rapid translation of medical innovations into commercially successful businesses, including technology transfer from universities to spin outs. Also supporting the growth of high potential life science businesses.Specialties: Strategic, operational and management analyses and advice. Pharmaceuticals, diagnostics, medical devices, biotechnology, healthcare, spin outs, technology transfer, medical innovation.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.